Amicus Therapeutics Company Insiders
FOLD Stock | USD 11.78 0.08 0.67% |
Amicus Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Amicus Therapeutics suggests that all insiders are panicking. Amicus Therapeutics employs about 517 people. The company is managed by 41 executives with a total tenure of roughly 317 years, averaging almost 7.0 years of service per executive, having 12.61 employees per reported executive.
John Crowley Chairman Executive Chairman |
Hung Do President Senior Vice President - Discovery Biology |
Amicus Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-03-05 | Margaret G Mcglynn | Disposed 7500 @ 13.4 | View | ||
2024-02-15 | Bradley L Campbell | Disposed 4167 @ 14 | View | ||
2024-02-06 | Ellen Rosenberg | Disposed 400 @ 13 | View | ||
2024-01-22 | John F Crowley | Disposed 55327 @ 12.36 | View | ||
2024-01-16 | John F Crowley | Disposed 31614 @ 12.78 | View | ||
2024-01-10 | John F Crowley | Disposed 31614 @ 13.65 | View | ||
2024-01-09 | David Michael Clark | Disposed 1384 @ 14 | View | ||
2024-01-08 | Samantha Prout | Disposed 30767 @ 14 | View | ||
2024-01-02 | Bradley L Campbell | Disposed 15833 @ 14.23 | View | ||
2023-12-27 | Ellen Rosenberg | Disposed 5000 @ 14.07 | View | ||
2023-12-26 | Samantha Prout | Disposed 7659 @ 14 | View | ||
2023-12-19 | Jeff Castelli | Disposed 17500 @ 13.25 | View | ||
2023-12-15 | John F Crowley | Disposed 6043 @ 12.66 | View | ||
2023-12-01 | John F Crowley | Disposed 6043 @ 11.08 | View | ||
2023-11-15 | John F Crowley | Disposed 6043 @ 10.84 | View | ||
2023-11-01 | John F Crowley | Disposed 6044 @ 10.97 | View |
Monitoring Amicus Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Amicus |
Amicus Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Amicus Therapeutics' future performance. Based on our forecasts, it is anticipated that Amicus will maintain a workforce of about 520 employees by April 2024.Amicus Therapeutics' latest congressional trading
Congressional trading in companies like Amicus Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Amicus Therapeutics by those in governmental positions are based on the same information available to the general public.
2023-04-10 | Representative Daniel Goldman | Disposed Under $15K | Verify |
Amicus Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 29, 2024, Return On Capital Employed is expected to decline to -0.13. In addition to that, Return On Assets is expected to decline to -0.2. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 7.23, whereas Other Assets are forecasted to decline to about 41.8 M.The current year's Common Stock Shares Outstanding is expected to grow to about 309.9 M, whereas Net Loss is forecasted to decline to (223.6 M).
Amicus Therapeutics Workforce Comparison
Amicus Therapeutics is rated # 2 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,497. Amicus Therapeutics totals roughly 517 in number of employees claiming about 35% of equities under Health Care industry.
Amicus Therapeutics Profit Margins
The company has Profit Margin (PM) of (0.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.03.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.7 | 0.8868 |
|
|
Amicus Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amicus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amicus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amicus Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.4386 | 25 | 57 | 1,628,934 | 995,200 |
2023-12-01 | 0.4348 | 10 | 23 | 148,755 | 244,055 |
2023-09-01 | 0.3 | 9 | 30 | 368,025 | 380,794 |
2023-06-01 | 1.4 | 21 | 15 | 362,564 | 129,764 |
2023-03-01 | 0.5 | 25 | 50 | 2,630,315 | 1,056,570 |
2022-12-01 | 0.2 | 3 | 15 | 16,425 | 212,069 |
2022-09-01 | 0.1579 | 3 | 19 | 16,410 | 147,312 |
2022-06-01 | 1.0 | 15 | 15 | 490,901 | 189,862 |
2022-03-01 | 0.7692 | 20 | 26 | 2,364,302 | 422,148 |
2021-12-01 | 0.3913 | 9 | 23 | 112,219 | 340,543 |
2021-09-01 | 0.6316 | 12 | 19 | 112,206 | 257,842 |
2021-06-01 | 1.3636 | 45 | 33 | 892,615 | 1,539,199 |
2021-03-01 | 0.7436 | 29 | 39 | 1,094,452 | 540,130 |
2020-12-01 | 0.5814 | 25 | 43 | 436,879 | 966,785 |
2020-09-01 | 0.6545 | 36 | 55 | 633,805 | 1,263,958 |
2020-06-01 | 0.9268 | 38 | 41 | 455,820 | 457,348 |
2020-03-01 | 0.597 | 40 | 67 | 2,556,403 | 1,026,752 |
2019-12-01 | 0.3889 | 7 | 18 | 780,082 | 347,946 |
2019-09-01 | 0.6667 | 4 | 6 | 64,945 | 120,000 |
2019-06-01 | 1.7059 | 29 | 17 | 540,944 | 235,205 |
2019-03-01 | 1.0313 | 33 | 32 | 2,034,966 | 652,206 |
2018-12-01 | 1.3333 | 4 | 3 | 180,854 | 20,000 |
2018-09-01 | 1.2857 | 9 | 7 | 719,205 | 45,000 |
2018-06-01 | 1.2353 | 21 | 17 | 132,863 | 238,277 |
2018-03-01 | 1.0625 | 34 | 32 | 1,424,615 | 322,879 |
2017-12-01 | 0.4074 | 22 | 54 | 1,303,224 | 2,643,661 |
2017-09-01 | 1.6667 | 5 | 3 | 1,507,185 | 4,185 |
2017-06-01 | 2.5 | 20 | 8 | 234,264 | 102,250 |
2017-03-01 | 4.0 | 20 | 5 | 1,905,643 | 250,000 |
2016-12-01 | 1.75 | 7 | 4 | 514,508 | 55,716 |
2016-09-01 | 0.125 | 1 | 8 | 3,500 | 1,205,374 |
2016-03-01 | 1.75 | 14 | 8 | 1,175,000 | 205,874 |
2015-12-01 | 2.4286 | 17 | 7 | 919,443 | 90,006 |
2015-09-01 | 0.4375 | 14 | 32 | 267,511 | 511,316 |
2015-06-01 | 0.6341 | 52 | 82 | 1,955,240 | 1,150,894 |
2015-03-01 | 0.6591 | 29 | 44 | 1,362,904 | 913,280 |
2014-12-01 | 0.5 | 19 | 38 | 2,343,737 | 11,822,181 |
2014-09-01 | 0.5152 | 17 | 33 | 305,347 | 317,694 |
2014-06-01 | 41.0 | 41 | 1 | 5,851,491 | 16,491 |
2014-03-01 | 2.0 | 16 | 8 | 1,091,608 | 445,175 |
2013-12-01 | 0.4 | 2 | 5 | 20,000 | 65,000 |
2013-03-01 | 1.1111 | 10 | 9 | 593,756 | 132,000 |
2012-09-01 | 1.0 | 1 | 1 | 30,000 | 10,000 |
2012-06-01 | 7.0 | 14 | 2 | 778,750 | 205,000 |
2012-03-01 | 14.0 | 14 | 1 | 3,730,085 | 49,931 |
2011-06-01 | 4.3333 | 13 | 3 | 457,250 | 14,500 |
2011-03-01 | 0.4706 | 8 | 17 | 360,000 | 190,000 |
2010-06-01 | 2.0 | 10 | 5 | 217,500 | 67,834 |
2010-03-01 | 2.0 | 2 | 1 | 23,796 | 9,500 |
2009-12-01 | 1.2 | 6 | 5 | 420,000 | 44,835 |
2009-06-01 | 1.0 | 3 | 3 | 30,000 | 12,791 |
2009-03-01 | 0.8889 | 8 | 9 | 293,924 | 17,834 |
2008-12-01 | 0.0303 | 3 | 99 | 60,098 | 202,390 |
2008-06-01 | 0.0327 | 7 | 214 | 90,000 | 71,250 |
2008-03-01 | 34.9565 | 1608 | 46 | 1,658,581 | 122,583 |
2007-12-01 | 1.0 | 2 | 2 | 15,000 | 15,000 |
2007-09-01 | 105.0 | 105 | 1 | 261,460 | 32,366 |
2007-06-01 | 2.1628 | 186 | 86 | 33,414,058 | 15,594,354 |
Amicus Therapeutics Notable Stakeholders
An Amicus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amicus Therapeutics often face trade-offs trying to please all of them. Amicus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amicus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bradley MBA | President CEO | Profile | |
John Crowley | Executive Chairman | Profile | |
Hung Do | Senior Vice President - Discovery Biology | Profile | |
John Kirk | Vice President - Regulatory Affairs | Profile | |
Andrew Mulberg | Vice President - Regulatory Strategy | Profile | |
Enrique Dilone | Vice President - Technical Operations | Profile | |
Dipal Doshi | Senior Vice President - Business Planning and Development | Profile | |
Mark Baldry | Vice President of Global Marketing | Profile | |
Kenneth Peist | Vice President - Legal and Intellectual Property | Profile | |
Ken Valenzano | Senior Vice President - Preclinical Research | Profile | |
Jayne Gershkowitz | Vice President - Patient Advocacy & Public Policy | Profile | |
Willem Weperen | Regional Vice President and Country Manager, International | Profile | |
Julie Yu | Vice President - Clinical Operations and Data Management | Profile | |
David Allsop | Senior Vice President - International | Profile | |
Simon Jordan | Senior Vice President - International | Profile | |
Jill Weimer | Senior Vice President of Discovery Research and Gene Therapy Science | Profile | |
Jeffrey Castelli | Vice President - Program and Portfolio Management | Profile | |
Kurt Andrews | Senior Vice President - Human Resources | Profile | |
William Baird | CFO | Profile | |
Bradley Campbell | Pres and COO | Profile | |
Robert Essner | Independent Director | Profile | |
Craig Wheeler | Independent Director | Profile | |
Burke Whitman | Independent Director | Profile | |
Margaret McGlynn | Independent Director | Profile | |
Ted Love | Independent Director | Profile | |
Donald Hayden | Lead Independent Director | Profile | |
Michael Raab | Independent Director | Profile | |
Sol Barer | Independent Director | Profile | |
Lynn Bleil | Independent Director | Profile | |
Glenn Sblendorio | Independent Director | Profile | |
Daphne Quimi | Principal Accounting Officer, VP of Fin. and Corporate Controller | Profile | |
David Clark | Chief Officer | Profile | |
Samantha Prout | Principal Accounting Officer, Controller | Profile | |
Andrew Faughnan | Director Relations | Profile | |
Diana Moore | Head Communications | Profile | |
Jay Barth | Chief Medical Officer | Profile | |
Patrik Esq | Global Officer | Profile | |
Sara Pellegrino | IR Contact Officer | Profile | |
Patrik Florencio | Global VP | Profile | |
Simon Harford | Chief Officer | Profile | |
Ellen Rosenberg | General Counsel and Corporate Secretary | Profile |
About Amicus Therapeutics Management Performance
The success or failure of an entity such as Amicus Therapeutics often depends on how effective the management is. Amicus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amicus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amicus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.12) | (0.13) | |
Return On Assets | (0.19) | (0.20) | |
Return On Equity | (0.95) | (0.99) |
The data published in Amicus Therapeutics' official financial statements usually reflect Amicus Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Amicus Therapeutics. For example, before you start analyzing numbers published by Amicus accountants, it's critical to develop an understanding of what Amicus Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Amicus Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amicus Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Amicus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amicus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Amicus Therapeutics' management manipulating its earnings.
Amicus Therapeutics Workforce Analysis
Traditionally, organizations such as Amicus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amicus Therapeutics within its industry.Amicus Therapeutics Manpower Efficiency
Return on Amicus Therapeutics Manpower
Revenue Per Employee | 772.4K | |
Revenue Per Executive | 9.7M | |
Net Loss Per Employee | 293.2K | |
Net Loss Per Executive | 3.7M | |
Working Capital Per Employee | 610K | |
Working Capital Per Executive | 7.7M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.